[HTML][HTML] Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy
M Karahoca, RL Momparler - Clinical epigenetics, 2013 - Springer
Aza-2′-deoxycytidine (5-AZA-CdR, decitabine), an epigenetic drug that inhibits DNA
methylation, is currently used to treat myelodysplastic syndrome (MDS), and is under …
methylation, is currently used to treat myelodysplastic syndrome (MDS), and is under …
[PDF][PDF] Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy
M Karahoca, RL Momparler - 2013 - scienceopen.com
Aza-2′-deoxycytidine (5-AZA-CdR, decitabine), an epigenetic drug that inhibits DNA
methylation, is currently used to treat myelodysplastic syndrome (MDS), and is under …
methylation, is currently used to treat myelodysplastic syndrome (MDS), and is under …
[PDF][PDF] Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy
M Karahoca, RL Momparler - 2013 - core.ac.uk
Aza-2′-deoxycytidine (5-AZA-CdR, decitabine), an epigenetic drug that inhibits DNA
methylation, is currently used to treat myelodysplastic syndrome (MDS), and is under …
methylation, is currently used to treat myelodysplastic syndrome (MDS), and is under …
[PDF][PDF] Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy
M Karahoca, RL Momparler - 2013 - Citeseer
Aza-2′-deoxycytidine (5-AZA-CdR, decitabine), an epigenetic drug that inhibits DNA
methylation, is currently used to treat myelodysplastic syndrome (MDS), and is under …
methylation, is currently used to treat myelodysplastic syndrome (MDS), and is under …
[引用][C] Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy
M Karahoca, RL Momparler - Clinical Epigenetics, 2013 - cir.nii.ac.jp
Pharmacokinetic and pharmacodynamic analysis of 5-aza-2’-deoxycytidine (decitabine) in the
design of its dose-schedule for cancer therapy | CiNii Research CiNii 国立情報学研究所 学術 …
design of its dose-schedule for cancer therapy | CiNii Research CiNii 国立情報学研究所 学術 …
[PDF][PDF] Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy
M Karahoca, RL Momparler - 2013 - researchgate.net
Aza-2′-deoxycytidine (5-AZA-CdR, decitabine), an epigenetic drug that inhibits DNA
methylation, is currently used to treat myelodysplastic syndrome (MDS), and is under …
methylation, is currently used to treat myelodysplastic syndrome (MDS), and is under …
[HTML][HTML] Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy
M Karahoca, RL Momparler - Clinical …, 2013 - clinicalepigeneticsjournal …
5-Aza-2′-deoxycytidine (5-AZA-CdR, decitabine), an epigenetic drug that inhibits DNA
methylation, is currently used to treat myelodysplastic syndrome (MDS), and is under …
methylation, is currently used to treat myelodysplastic syndrome (MDS), and is under …
Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy.
M Karahoca, RL Momparler - Clinical Epigenetics, 2013 - europepmc.org
Aza-2′-deoxycytidine (5-AZA-CdR, decitabine), an epigenetic drug that inhibits DNA
methylation, is currently used to treat myelodysplastic syndrome (MDS), and is under …
methylation, is currently used to treat myelodysplastic syndrome (MDS), and is under …
Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy
M Karahoca, RL Momparler - Clinical epigenetics, 2013 - pubmed.ncbi.nlm.nih.gov
5-Aza-2'-deoxycytidine (5-AZA-CdR, decitabine), an epigenetic drug that inhibits DNA
methylation, is currently used to treat myelodysplastic syndrome (MDS), and is under …
methylation, is currently used to treat myelodysplastic syndrome (MDS), and is under …
[HTML][HTML] Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy
M Karahoca, RL Momparler - Clinical Epigenetics, 2013 - ncbi.nlm.nih.gov
Aza-2′-deoxycytidine (5-AZA-CdR, decitabine), an epigenetic drug that inhibits DNA
methylation, is currently used to treat myelodysplastic syndrome (MDS), and is under …
methylation, is currently used to treat myelodysplastic syndrome (MDS), and is under …